يعرض 1 - 5 نتائج من 5 نتيجة بحث عن '"Lahn, Michael M. F."', وقت الاستعلام: 1.40s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

    المؤلفون: Melisi, Davide, García-Carbonero, Rocío, Macarulla Mercadé, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Oettle, Helmut, Kozloff, Mark, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Gueorguieva, Ivelina, Lahn, Michael M. F., Blunt, Al, Benhadji, Karim A., Tabernero, Josep, Universitat Autònoma de Barcelona

    مصطلحات موضوعية: Cancer immunotherapy, Prognostic markers, Predictive markers

    وصف الملف: application/pdf

    العلاقة: British Journal of Cancer; Vol. 119 (october 2018), p. 1208-1214; https://ddd.uab.cat/record/228042Test; urn:10.1038/s41416-018-0246-z; urn:oai:ddd.uab.cat:228042; urn:pmid:30318515; urn:pmcid:PMC6251034; urn:pmc-uid:6251034; urn:articleid:15321827v119p1208; urn:oai:egreta.uab.cat:publications/d6996337-ed78-4695-ba58-75d216dad8c9; urn:scopus_id:85055129225; urn:oai:pubmedcentral.nih.gov:6251034

    الإتاحة: https://ddd.uab.cat/record/228042Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

    المؤلفون: Ikeda, Masafumi, Morimoto, Manabu, Tajimi, Masaomi, Inoue, Koichi, Benhadji, Karim A., Lahn, Michael M. F., Sakai, Daisuke

    المصدر: Investigational New Drugs ; volume 37, issue 1, page 118-126 ; ISSN 0167-6997 1573-0646

    مصطلحات موضوعية: Pharmacology (medical), Pharmacology, Oncology

    الإتاحة: https://doi.org/10.1007/s10637-018-0636-3Test

    View record in BASE

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

    المؤلفون: Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Kozloff, Mark, Simionato, Francesca, Cleverly, Ann, Smith, Claire, Wang, Shuaicheng, Man, Michael, Driscoll, Kyla E, Estrem, Shawn T, Lahn, Michael M F, Benhadji, Karim A, Tabernero, Josep

    المساهمون: Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Deni, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Kozloff, Mark, Simionato, Francesca, Cleverly, Ann, Smith, Claire, Wang, Shuaicheng, Man, Michael, Driscoll, Kyla E, Estrem, Shawn T, Lahn, Michael M F, Benhadji, Karim A, Tabernero, Josep

    مصطلحات موضوعية: CA19-9

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30887178; info:eu-repo/semantics/altIdentifier/wos/WOS:000464844100018; volume:83; issue:5; firstpage:975-991; lastpage:991; numberofpages:16; journal:CANCER CHEMOTHERAPY AND PHARMACOLOGY; http://hdl.handle.net/11562/1014022Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85063234064

    الإتاحة: https://doi.org/10.1007/s00280-019-03807-4Test
    http://hdl.handle.net/11562/1014022Test

    View record in BASE

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.

    المؤلفون: Ikeda, Masafumi, Morimoto, Manabu, Tajimi, Masaomi, Inoue, Koichi, Benhadji, Karim A., Lahn, Michael M. F., Sakai, Daisuke

    المصدر: Investigational New Drugs; Feb2019, Vol. 37 Issue 1, p118-126, 9p

    مصطلحات موضوعية: ANTINEOPLASTIC agents, CLINICAL trials, DRUG dosage, DRUG side effects, CLINICAL drug trials, DRUG toxicity, HEPATOCELLULAR carcinoma, JAPANESE people, MEDICAL cooperation, ORAL drug administration, RESEARCH, TRANSFORMING growth factors-beta, TREATMENT effectiveness, HYPOPHOSPHATEMIA, PLATELET count, PROTEIN kinase inhibitors, HAND-foot syndrome, THERAPEUTICS

    مصطلحات جغرافية: JAPAN

    النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).

    المؤلفون: Di Giacomo, Anna Maria, Santangelo, Federica, Amato, Giovanni, Simonetti, Elena, Graham, Jill, Lahn, Michael M. F., Di Conza, Giusy, Hammett, Tracey, Zorrilla, Rebeca, Durini, Marco, Tan, Ziyang, Tadepally, Lakshmikanth, Brodin, Petter, Occhipinti, Mariaelena, Simonelli, Matteo, Carlo-Stella, Carmelo, Santoro, Armando, Spiliopoulou, Pavlina, Evans, T.R. Jeffry, Maio, Michele

    المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p3110-3110, 1p


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث